- Andreas Bergthaler Group
- Christoph Binder Group
- Christoph Bock Group
- Sylvia Knapp Group
- Robert Kralovics Group
- Stefan Kubicek Group
- Joanna I. Loizou Group
- Jörg Menche Group
- Giulio Superti-Furga Group
- Georg Winter Group
- Chemical Screening, Proteomics and Metabolomics Facility
- Biomedical Sequencing Facility (BSF)
- Keiryn Bennett (Senior Researcher on Leave)
- Denise P. Barlow (retired in 2015)
In a public-private partnership between CeMM, Boehringer Ingelheim, and Haplogen, the CD Lab for Chemical Epigenetics and Antiinfectives aims to develop novel screening technologies and identify chemical probe compounds as a basis for future drug development projects with the corporate partners.
In the chemical epigenetics module we develop technologies in collaboration with Oncology Research at Boehringer Ingelheim RCV GmbH & Co KG to identify and characterize small molecules and druggable proteins regulating chromatin structure and function. In a second module, we identify chemical probes for host factors of infectious diseases based on molecular targets derived by a powerful screening approach using human haploid cells implemented at Haplogen GmbH. Bringing these targets together with CeMM’s comprehensive compound library and screening expertise will generate novel chemical probes that can be used for proof-of-concept studies.